Evidence-based clinical standard for the diagnosis and treatment of invasive lung aspergillosis in the patient with oncohematologic disease
Aspergillosis is a disease caused by the filamentous fungus Aspergillus spp. with a spectrum of clinical presentation that includes invasive and noninvasive forms. The invasive clinical presentation of aspergillosis most frequently affects people with compromised immune systems. In patients with oncohematologic pathology, invasive lung aspergillosis is a significant opportunistic mycosis, because it occurs frequently and has a major impact on morbidity, mortality, and high costs. The global problem of antimicrobial resistance, to which improper use of antifungals contributes, has put Aspergilus spp. in the spotlight, so it is important to generate guidelines for guidance in the proper use of antifungals in the management of invasive lung aspergillosis, to obtain better clinical outcomes and promote rational use of antifungals. This guideline contains recommendations for diagnosing and treating invasive lung aspergillosis in patients with oncohematologic disease, based on evidence and defined through a participatory process of expert consensus, for the Latin American context.
Authors
- Márcio Nucci (ORCID: https://orcid.org/0000-0003-4867-0014)
- José Luis Sandoval‐Gutiérrez
- Mauricio Sarmiento (ORCID: https://orcid.org/0000-0003-3715-9886)
- Sonia Isabel Cuervo (ORCID: https://orcid.org/0000-0001-5676-880X)
- Laura Cristina Nócua-Báez (ORCID: https://orcid.org/0000-0003-2869-2339)
- Leonardo Enciso-Olivera (ORCID: https://orcid.org/0000-0001-5540-1969)
- Diego Andrés Rodríguez Lugo (ORCID: https://orcid.org/0000-0002-4251-7871)
- Fabio Varón-Vega (ORCID: https://orcid.org/0000-0002-4000-6007)
- Ricardo Rabagliati (ORCID: https://orcid.org/0000-0002-0574-8312)
- Fernando Riera (ORCID: https://orcid.org/0000-0002-0618-1899)
- Martha Carolina Valderrama-Ríos
- Beatriz L. Gómez (ORCID: https://orcid.org/0000-0002-6641-1924)
- Diana Lorena Ochoa
- Dora Corzo-León (ORCID: https://orcid.org/0000-0003-4012-1045)
- Carlos Álvarez (ORCID: https://orcid.org/0000-0001-5419-4494)
- Cándida Díaz‐Brochero (ORCID: https://orcid.org/0000-0002-2176-7388)
- Patricia Cornejo‐Juárez (ORCID: https://orcid.org/0000-0001-6331-8372)
- Adriana Marcela Celis Ramírez (ORCID: https://orcid.org/0000-0003-3057-1966)
- Luis E. Cuéllar
- Jorge Alberto Cortés (ORCID: https://orcid.org/0000-0002-0882-9652)
- E. Vergara
- Domênico Capone
- Rita Rojas
- Luis Thompson
Institutions
- Federico Villarreal National University (PE)
- Universidade Federal do Rio de Janeiro (BR)
- Universidad del Desarrollo (CL)
- Universidad de Los Andes (CO)
- Pontificia Universidad Católica de Chile (CL)
- Pontificia Universidad Javeriana (CO)
- Exeter City Council (GB)
- Instituto Tecnológico de Santo Domingo (DO)
- Universidad Nacional de Colombia (CO)
- Universidade do Estado do Rio de Janeiro (BR)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Instituto Nacional de Cancerología (CO)
- Fundación Neumológica Colombiana (CO)
- Instituto Nacional de Enfermedades Neoplásicas (PE)
- Instituto Nacional de Cancerología (MX)
- Hospital Universitario Nacional de Colombia (CO)
- Hospital Universitario Infantil San José (CO)
- Fundacion Allende (AR)
- Universidad del Rosario (CO)
Publication Details
- Journal
- The Brazilian Journal of Infectious Diseases
- Published
- 2025-02-24
- DOI
- https://doi.org/10.1016/j.bjid.2025.104517
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer